



SICAV Range

JPMorgan Funds - Global Healthcare Fund

- The Fund invests primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally.
- The Fund is therefore exposed to risks related to equity, concentration, Healthcare Companies, smaller companies, currency, derivative and hedging.
- Investors may be subject to substantial losses.
- Investors should not solely rely on this document to make any investment decision.

Fund overview

Investment objective

To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally.

Expertise

Fund Manager

Dom Valder, Bartjan van Hulten

Fund Information (A (acc) - USD)

Fund base currency
USD

Denominated currency and NAV per unit

Total fund size (m)
USD 4,727.5

A (acc) - USD : USD 506.60

12 month NAV

High : USD 514.63 (26/02/24)

Low : USD 417.30 (30/10/23)

SEDOL

B558K58

ISIN code

LU0432979614

Bloomberg code

JPHLUA LX

Current charge

Initial : 5.0% of NAV

Redemption : 0%

Management fee : 1.5% p.a.

Ratings

Medalist Rating

Bronze

Analyst-Driven %

10

Data Coverage %

99

Category

Sector Equity Healthcare

Risk


1 2 3 4 5

Performance

Cumulative Performance (%)

JPM Global Healthcare A (acc) - USD

MSCI World Healthcare Index (Total Return Net)¹⁾



	1 month	1 year	3 years	5 years	Since launch	Launch date
A (acc) - USD ³⁾	3.1	11.4	9.6	48.9	433.8	02/10/09
Benchmark ¹⁾	2.3	14.3	25.6	61.1	389.2	

Calendar Year Performance (%)

	2019	2020	2021	2022	2023	2024YTD
A (acc) - USD ³⁾	21.4	23.5	11.1	-9.3	2.7	5.5
Benchmark ¹⁾	23.2	13.5	19.8	-5.4	3.8	5.0

¹⁾Dividends reinvested after deduction of withholding tax. ²⁾This share class is not available on the J.P. Morgan eTrading platform. ³⁾Available for purchase in Hong Kong on 01.11.21. ⁴⁾With the exception of the "Average annual return" figure, all data are calculated from the month end after inception. ⁵⁾Investments in, or exposure to, any single entity (other than Government and other public securities) cannot exceed 10% of the Fund's total net asset value. ⁶⁾Issued by Asian Investor, 2022 award, reflecting performance as at the previous calendar year end. ⁷⁾Issued by Refinitiv Lipper, 2023 award reflecting performance as of 31.12.2022. Refinitiv Lipper Fund Awards, 2023 Refinitiv. All rights reserved. Used by permission and protected by the Copyright Laws of the United States. The printing, copying, redistribution, or retransmission of this content without express written permission is prohibited. Unless stated otherwise, all information as at the last valuation date of the previous month. Source: J.P. Morgan Asset Management/Factset (NAV to NAV in denominated currency with income reinvested). Risk ratings (if any) are based on J.P. Morgan Asset Management's assessment of relative risk by asset class and historical volatility of the fund where applicable. The risk ratings are reviewed annually or as appropriate and for reference only. Any overweight in any investment holding exceeding the limit set out in the Investment Restrictions was due to market movements and will be rectified shortly. It should be noted that due to the difference of the fund domiciles the valuation points used by Unit Trust range and SICAV range of funds for fair valuation (where applied) may vary. For details please refer to the respective offering document(s).
Investment involves risk. Past performance is not indicative of future performance. Please refer to the offering document(s) for details, including the risk factors. This document has not been reviewed by the SFC. Issued by JPMorgan Funds (Asia) Limited.
For more information, please contact your bank, financial adviser or visit am.jpmorgan.com/hk today.

Portfolio Analysis (A (acc) - USD)


	3 years	5 years	Since Launch ⁴⁾
Correlation	0.90	0.93	0.92
Annualized Alpha %	-3.76	-1.31	0.02
Beta	0.92	0.99	1.08
Annualised volatility %	14.47	15.50	15.39
Sharpe ratio	0.03	0.39	0.72
Annualised tracking error %	6.45	5.69	6.22
Average annual return %	3.12	8.29	12.32

Holdings⁵⁾ (as at end February 2024)


TOP 10	Sector	%
Eli Lilly	Pharmaceutical	9.1
UnitedHealth	Healthcare Services	7.8
Novo Nordisk	Pharmaceutical	5.8
ABBVIE	Biotechnology	4.8
Regeneron Pharmaceuticals	Biotechnology	4.6
AstraZeneca	Pharmaceutical	4.3
Danaher	Medtech	3.7
Johnson & Johnson	Pharmaceutical	3.0
Centene	Healthcare Services	2.9
Stryker	Medtech	2.6

Portfolio Breakdown

Market



Sector

Scan the QR code
for fund documents

¹⁾Dividends reinvested after deduction of withholding tax. ²⁾This share class is not available on the J.P. Morgan eTrading platform. ³⁾Available for purchase in Hong Kong on 01.11.21. ⁴⁾With the exception of the "Average annual return" figure, all data are calculated from the month end after inception. ⁵⁾Investments in, or exposure to, any single entity (other than Government and other public securities) cannot exceed 10% of the Fund's total net asset value. ⁶⁾Issued by AsianInvestor, 2022 award, reflecting performance as at the previous calendar year end. ⁷⁾Issued by Refinitiv Lipper, 2023 award reflecting performance as of 31.12.2022. Refinitiv Lipper Fund Awards, 2023 Refinitiv. All rights reserved. Used by permission and protected by the Copyright Laws of the United States. The printing, copying, redistribution, or retransmission of this content without express written permission is prohibited. Unless stated otherwise, all information as at the last valuation date of the previous month. Source: J.P. Morgan Asset Management/Factset (NAV to NAV in denominated currency with income reinvested). Risk ratings (if any) are based on J.P. Morgan Asset Management's assessment of relative risk by asset class and historical volatility of the fund where applicable. The risk ratings are reviewed annually or as appropriate and for reference only. Any overweight in any investment holding exceeding the limit set out in the Investment Restrictions was due to market movements and will be rectified shortly. It should be noted that due to the difference of the fund domiciles the valuation points used by Unit Trust range and SICAV range of funds for fair valuation (where applied) may vary. For details please refer to the respective offering document(s).

Investment involves risk. Past performance is not indicative of future performance. Please refer to the offering document(s) for details, including the risk factors. This document has not been reviewed by the SFC. Issued by JPMorgan Funds (Asia) Limited. For more information, please contact your bank, financial adviser or visit am.jpmorgan.com/hk today.